Company*
(Country; Symbol)

Funding
Institution

Amount
(M)

Type#

Details (Date)


Active Pass
Pharmaceuticals
Inc.*
(Canada)

National Institute
of Allergy and Infectious Diseases

C$3.6
(US$2.85)

Grant

The award will support development of a treatment for secretory diarrhea (10/1)

Adenosine
Therapeutics
LLC*

National Institutes
of Health

$1.25

Phase II SBIR grant

The grant will fund research with the University of Virginia to test the combination of two anti-inflammatory drugs, ATL146e and a Type IV PDE inhibitor, in a drug-eluting stent (12/6)

Affymetrix
Inc.
(AFFX)

National Institute
of Allergy and Infectious Diseases

$2.1

Grant

To develop a biodefense microarray test that can detect hundreds of bacterial and viral biological threats (10/19)

Althea
Technologies
Inc.*

National Cancer
Institute

ND

Phase I SBIR grant

To establish validated, quantitative gene expression assays that serve as "genetic signatures" for diagnosing multiple pediatric cancers (10/19)

Amyris
Biotechnologies
Inc.*

Bill and Melinda
Gates Foundation

$12

Grant

Amyris will get $12M of a $42.6M grant that is funding work on an affordable drug for malaria; also working on the project are One-World Health and the University of California at Berkeley (12/13)

Attenuon
LLC*

National Cancer
Institute

$0.358

Phase I/II STTR grant

To evaluate derivatives of the peptide ATN-161 as agents for PET imaging; another $942,000 could be awarded for years two and three if milestones are met (10/28)

BioLineRx
Ltd.*
(Israel)

Israeli Office of
the Chief Scientist

$21

Grant

The company said it was the sole recipient of a grant for development of preclinical compounds as part of an initiative to advance the industry in Israel (12/2)

Biolog Inc.*

National Institutes
of Health

ND

STTR grant

To collaborate with Johns Hopkins University to develop Biolog's Phenotype MicroArray technology to study gene function in Saccharomyces cerevisiae (10/25)

Biolog Inc.*

National Institutes
of Health

ND

STTR grant

To collaborate with Washington University to develop Biolog's Phenotype MicroArray technology for use with fastidious pathogens (10/21)

Biolog Inc.*

National Institutes
of Health

$2.5

Phase II SBIR grant

To further develop a cell-based assay as an in vitro replacement to animal models in some toxicology testing applications (10/13)

Bionomics
Ltd.
(Australia;
ASX:BNO)

Federal government
of Australia

A$0.247 (US$0.19)

Biotechnology Innovation Fund grant

To support work on developing targets for antibody treatments which inhibit blood vessel formation (angiogenesis) in cancer and other diseases (11/4)

Biophage
Pharma Inc.
(Canada; VSE:BUG)

Canadian
International Development Agency

ND

Financial support

To help open the Brazilian market to Biophage's therapeutic and diagnostic products (10/15)

Biota
Holdings
Ltd.
(Australia;
ASX:BTA)

National Institute
of Allergy and Infectious Diseases

$5.6

Grant

For development of a new influenza drug as part of the NIH's pandemic preparedness strategy (9/30)#

BioTie
Therapies
Corp.
(Finland;
HEX:BTH1V)

The National
Technology Agency of Finland

€3.3 (US$4.5)

R&D support

The loan and subsidy will support development of the VAP-1 SSAO small-molecule inhibitor program from August 2004 to July 2006 (11/17)

Bioxel Pharma
Inc.*
(Canada;
TSE:BIP)

Investissement Quebec Immigrant Investors

C$0.5 (US$0.4)

Financial contribution

Bioxel will get the money in four annual installments as part of a program to help businesses (10/7)

Cambridge
Biostability
Ltd.*
(UK)

Department for International Development (UK)

£0.950 (US$1.76)

Grant

To apply its glass-stabilizing technology to develop a pentavalent vaccine in a temperature-stable liquid form for use in developing countries (10/21)

Cangene
Corp.
(Canada;
TSE:CNJ)

Centers for Disease Control and Prevention

ND

Contract award

The CDC intends to negotiate a sole-source agreement for Cangene to provide up to 200,000 doses of botulinum toxin immune globulin (10/18)

Carrington
Laboratories
Inc.
(CARN)

National Institute
of Allergy and Infectious Diseases

$6

Grant

Three-year grant will fund work on an inactivated influenza nasal powder vaccine against the H5N1 strain, using its GelVac delivery system (10/5)

Cellartis AB*
(Sweden)

National Institutes
of Health

ND

Infrastructure award

The NIH granted a second year of funding for further work on human embryonic stem cell lines derived before Aug. 9, 2001 (10/19)

Cortical Pty.
Ltd.*
(Australia)

Federal government of Australia

A$2.5 (US$1.93)

R&D Start
grant

The funds will support development of small-molecule macrophage migration inhibitory factors for inflammatory diseases (11/5)

CytImmune
Inc.*

National Institute
of Standards and Technology

$2

Advanced Technology Program award

For development of a semi-synthetic human immune system on colloidal gold nanoparticles, for production of fully human monoclonal antibodies (11/18)

DeCode
Genetics
Inc.
(Iceland;
DCGN)

National Institute
of Allergy and Infectious Diseases

$23.9

Contract available to researchers (10/8)

DeCode will apply its population approach to discover genetic factors associated with susceptibility to certain infectious diseases and with vaccine response; the National Center for Genome Resources will provide bioinformatics resources to make results

Elusys
Therapeutics
Inc.*

National Institute
of Allergy and Infectious Diseases and the Department of Defense

$5.5 and $3

Funding support and grant

To support development and research for Anthim (ETI-204), an antibody treatment for exposure to anthrax toxin (10/13)

Endocyte
Inc.*

National Cancer Institute and the Indiana 21st Century Research and Technology Fund

$3.58

Grants

The NCI grant of $1.63M and the state grant of $1.95M will be used for preclinical tests using folate to transform cancer drugs into tumor-targeted agents (11/15)

EpiVax Inc.*

National Institutes
of Health's Institute of Allergy and Infectious Diseases

$0.994

BioDefense
Phase I SBIR
grant

The grant provides EpiVax with funds to develop a genome-derived, epitope-driven smallpox vaccine (12/20)

ES Cell
International
Pte. Ltd.*
(Singapore)

National Institutes
of Health

ND

Grant

Three-year grant will support human embryonic stem cell research (10/14)

454 Life
Sciences
(subsidiary
of CuraGen
Corp.; CRGN)

National Human Genome Research Institute

$5

Grant

Three-year grant will support development of the company's technology as a method to routinely sequence individual human genomes on PicoTiter-Plates (10/14)

Gene Logic
Inc.
(GLGC)

National Institute
on Drug Abuse

$6

Agreement

Gene Logic could get $6M over four years to provide preclinical safety and pharmacology studies focused on treating drug addiction (10/8)

GenoMed
Inc.
(OTC
BB:GMED)

National Institute
of Allergy and Infectious Diseases

ND

Contract
extension

For further testing of GenoMed's approach against viral diseases, including influenza (10/20)

Hawaii
Biotech Inc.*

National Institute
of Allergy and Infectious Diseases

$9.9

BioShield
grants

A $6.3M grant and a $3.3M grant will support preclinical and Phase I development of a vaccine for dengue virus (12/10)

Hawaii Biotech Inc.*

National Institute
of Neurological Disorders and Stroke

$5.9

Phase II SBIR grant

The grant will fund preclinical development of a West Nile virus vaccine (12/10)

Iconix
Pharma-
ceuticals Inc.*

National Cancer
Institute

ND

Phase I SBIR grant

The grant will support development of an in vitro system to detect specific forms of liver pathology (12/21)

ID Biomedical
Corp.
(Canada;
TSE:IDB)

National Institutes
of Health

$5.6

Grant

The grant of up to $5.6M will support development of a nasally administered subunit vaccine to protect against severe acute respiratory syndrome (10/1)

Isis Pharma-
ceuticals
Inc.
(ISIS)

Various U.S. government agencies

$10

Contract
awards

Three contracts valued at up to $10M will fund continued development of various applications of its TIGER biosensor technology (10/7)

Jerini AG*
(Germany)

German Federal
Ministry for Education and Research

€0.847 (US$1.1)

Funding
support

The money will support discovery and preclinical development of an orally available bradykinin B2 receptor antagonist (12/8)

KBI
BioPharma
Inc.*

National Science Foundation

$0.5

Phase II SBIR grant

To support the application of KBI's Centrifugal Bioreactor technology to biopharmaceutical production (10/20)

Kereos Inc.*

National Heart,
Lung and Blood Institute and Washington University

$7.3

Biomedical Research Partnership grant

The university's grant will support their work in developing ligand-targeted products for treating unstable plaque (11/18)

LAB
International
Inc.
(Canada;
TSE:LAB)

The National Technology Agency of Finland

C$4.6 (US$3.9)

R&D support

Finish subsidiary LAB Pharma will use the funds on its inhaled fentanyl formulation and for inhaled protein products (11/29)

Lynx
Therapeutics
Inc.
(LYNX)

National Science Foundation

ND

Research grant

The University of Delaware will use the grant to develop methods to capture and sequence small RNAs on a larger scale, using Lynx's MPSS technology (10/19)

Medarex
Inc.
(MEDX)

National Institute
of Allergy and Infectious Diseases

$7.6

Grants

Two milestone-driven grants over three years will support development of MDX-1303, a fully human antibody for anthrax infection (10/4)

Meridian
Bioscience
Inc.
(VIVO)

National Institutes
of Health

ND

Phase I SBIR grant

To develop specific recombinant antibodies to Clostridium difficile toxins A & B, and then use the antibodies to develop diagnostics (10/5)

Microchip
Biotech-
nologies
Inc.*

National Human Genome Research Institute

$6.1

Grant

To develop a nanofluidic technological platform that would reduce the cost of DNA sequencing (11/10)

Mirus Bio
Corp.*

National Institutes
of Health

$1.26

Phase II SBIR grant

To develop a gene-therapy product to treat anemia using its Pathway IV gene-delivery plat- form (10/6)

Mologen
AG
(Germany;
FSE:MGNG)

Innovation Support Program of Berlin

€0.212 (US$0.26)

Funding subsidy

The money will be used for final preclinical development of a cell-based, tumor-specific product for kidney cancer (10/5)

Newron
Pharma-
ceuticals
SpA*
(Italy)

European
Commission

€1.83 (US$2.5)

Cooperative Research Programme funding

Newron will lead a consortium to develop a high-throughput system for screening molecules that act on ion channel targets related to neurological diseases (12/1)

Novasite
Pharma-
ceuticals
Inc.*

National Institutes
of Health

$3.365

Bioengineering grant

The grant supports scale-up of Single Cell Screening technology for parallel screening of more than 100 G protein-coupled receptors (11/16)

Onyvax
Ltd.*
(UK)

European
Community

€1.6 (US$2.1)

Sixth Framework Program grant

Onyvax, Mubio Products BV, Cires GmbH, Medical Proteom-Center and the University of Maastricht make up the consortium that received the funds to develop vaccine therapies for lung cancer (10/29)

Perlegen
Sciences
Inc.*

National Institute
of Environmental Health Sciences

$13.2

Contract award

To identify sequence variation in inbred mouse strains; it will use Affymetrix Inc. technology in the work (10/26)

Potomac
Pharma Inc.*

Stanley Medical Research Center

$2.2

Funding support

To support development of P-101, Potomac's Phase II alpha-2 antagonist being developed for schizophrenia (10/19)

Progenics
Pharma-
ceuticals Inc.
(PGNX) and Cytogen Corp. (CYTO)

National Cancer
Institute

$7.4

Phase II SBIR grants

One grant will fund development of a fully human, PSMA-targeting monoclonal antibody for meta- static prostate cancer; the second will support development of a recombinant soluble PSMA vaccine (11/2)

Protalix
Biothera-
peutics Ltd.*
(Israel) and Icon Genetics AG* (Germany)

Governments
of Israel and Germany

ND

BIO-DISC grant

The funding will support their collaboration to develop genetic constructs as the basis for a platform for ultra-high-level expression of recombinant proteins in plant cells (11/12)

RiboNovix
Inc.*

National Institutes
of Health

$0.346

Phase I SBIR grant

For research to construct a functional E. coli rRNA mutation library and identify new anti-infective rRNA targets in E. coli (10/5)

RxGen Inc.*

National Institutes
of Health

$1.1

Fast-track SBIR grant

The company will use its genomics and bioinformatics technologies to discover genomic markers of Parkinson's disease (12/7)

RxGen Inc.*

National Institutes
of Health

$1.4

Phase I and II SBIR grants

To support development of PrimaTox as a platform to predict human toxic response to new pharmaceutical compounds (10/5)

Samaritan
Pharma-
ceuticals Inc.
(AMEX:LIV)

National Institutes
of Health

$0.1

STTR grant

The company and Georgetown University will use the grant to research SP-004, their Alzheimer's disease agent (10/19)

Stellar Bio-
technologies
Inc.*

National Cancer
Institute

$3

Phase II SBIR grant

Extension of the grant will fund development of technologies for its Keyhole Limpet Hemocyanin cancer vaccine program (10/4)

VaxGen Inc.
(OTC BB:VXGN)

U.S. government

$877.5

Contract

The contract under Project Bio- Shield calls for VaxGen to supply 75M doses of its recombinant Protective Antigen anthrax vaccine within three years for use in civilian defense (11/4)

VaxInnate
Corp.*

Department of
Health and Human Services

ND

Grant

The grant will be used to discover Toll-like receptor ligands with adjuvant properties (10/11)

VaxInnate
Corp.*

Department of
Health and Human Services

ND

Contract

To use its approach to discover and optimize Toll-like receptor ligands for use in vaccines against infectious diseases (10/11)


Notes:

* Indicates a privately held company.

Currency conversions reflect values at the time of a deal's announcement.

SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer.

# Item occured before the time frame on this chart but was not included in the previous chart.

Unless otherwise indicated, symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; HEX = Helsinki Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange.

No Comments